Send to

Choose Destination
Cancer Cell. 2012 Apr 17;21(4):451-3. doi: 10.1016/j.ccr.2012.03.027.

Breaking the LSD1/KDM1A addiction: therapeutic targeting of the epigenetic modifier in AML.

Author information

Oncology Institute, Loyola University Chicago, Maywood, IL 60153, USA.


KDM1A/LSD1, a histone H3K4/K9 demethylase and epigenetic regulator with roles in both gene activation and repression, has increased expression in multiple cancer types. Harris et al., in this issue of Cancer Cell, and Schenk et al. show that KDM1A may be a viable therapeutic target in treating AML.

Supplemental Content

Full text links

Icon for Elsevier Science Icon for PubMed Central
Loading ...
Support Center